Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2011

View Archived Issues

Phase II data reveal antitumor activity of SCH-727965 in breast cancer but not in NSCLC

Pfizer and UCSD describe PF-04449913, an oncolytic agent now in phase I development

AstraZeneca reports potent antidepressant/anxiolytic effects for AZD-2327 in vivo

GenKyoTex patents novel NADPH oxidase inhibitors

Cancer vaccines with tumor antigen H/K-HELP induce Th1 immune responses in patients

Small-molecule erythropoietin mimetic STS-E15 displays neuroprotective activity in vitro

Anavex begins dosing in phase I trial of ANAVEX 2-73 for Alzheimer's disease

Stanford University and SanBio begin phase I/II trial of cell therapy SB6-23 for stroke disability

New PRL-R-directed antibody LFA-102 shows promise as an oncolytic in preclinical tests

Qilu Pharma presents new receptor tyrosine-protein kinase inhibitors

Takeda claims novel ionotropic glutamate receptor agonists

New HSP 90 inhibitors synthesized by Aegera scientists

Chinese researchers prepare novel antibacterial and antifungal agents

Boston Scientific announces U.S. approval and launch of Ion paclitaxel-eluting stent

AIC-246 receives European orphan drug status for prevention of HCMV disease

Kyowa Hakko Kirin files NDA in Japan for KW-0761 in adult T-cell leukemia-lymphoma

Merck & Co. and Sanofi Pasteur begin phase III program for pediatric hexavalent combination vaccine

Mochida receives marketing approval in Japan for antidepressant Lexapro 10 mg

Tissue Genesis begins phase I/II trial of ASC-coated vascular grafts in peripheral vascular disease

European Commission approves Hizentra for primary and secondary immunodeficiencies

Kuros' phase IIb trial of KUR-113 in open tibial shaft fractures meets primary endpoint

Thymoglobuline is approved in Japan for treatment of acute renal transplant rejection

Japanese approval for Tramcet tablets for noncancer pain and pain after tooth extraction

Idera Pharma delays phase II study of IMO-2125 pending further toxicology results

Noscira begins phase IIb European trial of Nypta in Alzheimer's disease

Dosing begins in phase IIb study of TB-402 to prevent venous thromboembolism

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...